Michael Dunne, M.D., is Chief Medical Officer and Head of Development at Bill & Melinda Gates Medical Research Institute. He has held various senior level C-suite roles in connection with the clinical development of numerous infectious disease compounds including Chief Scientific Officer of Iterum Therapeutics where he now serves a Strategic Advisor on the Board of Directors. Dr. Dunne served as Chief Medical Officer of Durata Therapeutics which was acquired by Actavis in 2014. He worked at Pfizer in numerous roles of increasing responsibility including Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. Dr. Dunne received a B.A. in Economics from Northwestern University and M.D. from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.

Alex Dmitrienko, Ph.D, is Founder and President of Mediana LLC. He has been involved in clinical trial statistics for over 20 years and, prior to founding Mediana, was Vice President, Innovation Unit at Quintiles and Research Advisor, Advanced Analytics at Eli Lilly and Company. Dr. Dmitrienko is actively involved in biostatistical research and has published over 100 papers and five books on key topics in clinical trial statistics, including adaptive designs, multiple comparisons, biomarker analysis, and clinical trial optimization. He has served as an Associate Editor for The American Statistician, Biometrics and Statistics in Medicine, and is a Fellow of the American Statistical Association. Dr. Dmitrienko received a Ph.D. in Statistics from the University of Kentucky.

  1. Balfour Sartor, M.D., is the Midget Distinguished Professor of Medicine, Microbiology, and Immunology, Division of Gastroenterology and Hepatology, Co-Director of the National Institute of Diabetes and Digestive and Kidney Diseases-supported Center for Gastrointestinal Biology and Disease and Founder of the Multidisciplinary Inflammatory Bowel Disease (IBD) Center, University of North Carolina at Chapel Hill School of Medicine. Dr. Sartor’s clinical expertise focuses on managing patients with refractory IBD (Crohn’s disease, ulcerative colitis and pouchitis). His research investigates the ability of specific components of the intestinal microbiota to induce chronic T-cell mediated inflammation in genetically susceptible hosts vs. protective mucosal immune responses in normal hosts. Recently, he has investigated the ability of novel resident bacterial consortia to prevent and treat experimental colitis and their mechanisms of protection. Other recent research has extended microbial-host interaction studies to human samples, including mucosal biopsies and resected tissues from normal, Crohn’s disease and ulcerative colitis patients and to humanized mice. His lifelong contributions to better understand microbial influences in intestinal inflammation and protection have been recognized by the Basic Science Achievement Award from the American Gastroenterological Association and the Career Achievement Award from the Crohn’s and Colitis Foundation. He received a B.S. in Pre-Medicine from Washington-Lee University and a M.D. from Baylor College of Medicine. Fellowship training in Gastroenterology at University of North Carolina (UNC) at Chapel Hill, did his post-doctoral training in host-microbial interactions at UNC-Chapel Hill and advanced research training at the NIH.

Adam S. Cheifetz, M.D., is the Director of the Center for Inflammatory Bowel Disease (IBD) and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Assistant Director of the Advanced Fellowship in IBD at Beth Israel Deaconess Medical Center. Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple IBD research projects and has published over 200 articles and chapters on the subject. Dr. Cheifetz has also published extensively on his current research focus of optimizing biologic utilization through the proactive use of drug concentrations and antibodies. He is a fellow of the American Gastroenterological Association and American College of Gastroenterology. Dr. Cheifetz graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. He completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University before serving as the Present-Levinson Fellow in IBD at the Mount Sinai Medical Center.